Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Transcription Factor Targeting.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BHLHE41 (DEC2/SHARP1) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BHLHE41 Full-Length & bHLH Domain Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View BHLHE41 Products |
| Gene Delivery | BHLHE41 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. CMV promoter. |
View BHLHE41 Products |
| Benchmark Ab | Anti-BHLHE41 (ChIP-Grade) Recombinant monoclonal for IP/ChIP validation. |
View BHLHE41 Products |
| Validator | BHLHE41 siRNA Set (3 unique sequences) For knockdown and specificity verification. |
View BHLHE41 Products |
| Paralog Control | BHLHE40 (DEC1) Selectivity screening vs. closest family member (84% bHLH homology). |
View BHLHE40 Products |
| Interaction Partner | ARNTL (BMAL1) Heterodimerization partner for PPI assays. |
View ARNTL Products |
| Related Target | CLOCK Transcriptional complex component. |
View CLOCK Products |
| Related Target | HIF1A Synergistic pathway target involved in hypoxia regulation and tumor microenvironment modulation. |
View HIF1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| bHLH Family Selectivity (BHLHE40 vs BHLHE41) | Paralog protein pair available: BHLHE41 & BHLHE40 both >95% purity, verified by Mass Spec |
| Dimerization Interface Mapping | bHLH Domain fragments (aa 1-105) with native folding; suitable for SPR/ITC |
| DNA-Binding Negative Control | DNA-binding deficient mutant (R57A/R65A) available; eliminates non-specific DNA interactions |
| Cellular Target Engagement | Lentivirus + siRNA combo for gain/loss of function in circadian reporter assays |
| Intracellular Target Accessibility | High-titer Lentivirus enables robust stable cell line construction for phenotypic screening |
| Lack of Robust Expression Controls | Sequence Verified, Endotoxin Controlled recombinant positive controls included |
| False Positives in Gene Silencing | Validated siRNA included for precise specificity checks |
| Subfamily off-target liability (DEC1/DEC2 cross-reactivity) | Human BHLHE40 paralog protein available with >95% purity for parallel counter-screening |
| Mechanistic ambiguity (DNA-binding vs. PPI inhibition) | Truncated constructs (bHLH-only, Orange-only) and full-length protein strictly verified by mass spec |
| Lack of nuclear soluble standard for biophysical assays | Full-length BHLHE41 expressed in HEK293 with theoretical MW confirmed and endotoxin controlled |
| False positives from non-specific DNA/E-box binders | Validated siRNA included for target-specificity rescue experiments |
Live BHLHE41 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The targeting of BHLHE41 (also known as DEC2/SHARP1) represents a paradigm shift in transcription factor drug discovery. As a critical regulator of circadian rhythm, metabolism, and tumor suppression, BHLHE41 has emerged from "undruggable" status to a viable target for small molecule inhibitors and PROTAC degraders. Current R&D focuses on disrupting its heterodimerization with BMAL1 or blocking DNA binding, with applications spanning oncology (triple-negative breast cancer, prostate cancer) and metabolic disorders. Moreover, BHLHE41 is involved in hypoxia response and immune cell differentiation (Th2 cells, macrophage polarization), positioning it for immuno-oncology applications. The next wave of R&D is heavily targeting the tumor microenvironment by modulating BHLHE41 to overcome T-cell exhaustion and resistance to PD-1/PD-L1 checkpoint inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Consortia, Early Biotech | Solid Tumors, Circadian Sleep Disorders | Heterodimer Disruption (Need BHLHE41+BMAL1 proteins) |
| PROTAC / Protein Degrader | Arvinas-style platforms, Early-stage Biotechs | Triple-Negative Breast Cancer, Refractory Malignancies | Ternary Complex Validation (Need full-length native protein) |
| Peptide Inhibitor | Peptide-based biotech | Metabolic Syndrome | Competitive Binding Assay (Need high-purity bHLH domain) |
| siRNA / ASO | RNAi Therapeutics Companies | Metabolic Disorders / Oncology | Knockdown Validation (Need Lentivirus and specific siRNA) |
| Gene Modulation (Lentiviral) | Academic research groups | Immuno-oncology (T-cell engineering) | Stable reporter cell line generation (Need full-length ORF lentivirus) |
BHLHE41 Structure and Key Mutations
BHLHE41 contains two functional domains: a basic helix-loop-helix (bHLH) domain and an Orange domain (UniProt Q9C0J9). Key mutations in BHLHE41 affect sleep duration:
- VAR_082585: abolishes inhibition of CLOCK-BMAL1 and NPAS2/BMAL1 transcriptional activity
- VAR_082586: increases inhibition of CLOCK-BMAL1 and NPAS2/BMAL1 transcriptional activity
- VAR_063259: abolishes inhibition of CLOCK-BMAL1 and NPAS2/BMAL1 transcriptional activity
These mutations provide insights into circadian regulation and potential therapeutic modulation.